Karyopharm plunges as CMO steps down; clinical appointments
US cancer therapies specialist Karyopharm Therapeutics (Nasdaq: KPTI) saw its shares drop as much as 31% Tuesday, on the news that its chief medical officer was stepping down, even though it also announced two prominent research appointments.
Karyopharm announced changes to its clinical leadership team, including the appointment of Dr Patricia Judson as senior vice president of medical strategy and Stuart Poulton as SVP of strategy and portfolio management.
In addition, the company revealed that Dr Jatin Shah, executive VP and chief medical officer has stepped down to pursue other professional opportunities, but he will continue to serve Karyopharm in an advisory capacity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze